<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932217</url>
  </required_header>
  <id_info>
    <org_study_id>Pisa 01</org_study_id>
    <nct_id>NCT00932217</nct_id>
  </id_info>
  <brief_title>Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma</brief_title>
  <official_title>Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the difference in the incidence of febrile episodes in patients undergoing stem
      cells mobilization with chemotherapy and filgrastim versus chemotherapy and lenograstim.

      A febrile episode will be considered as: body temperature &gt; 38°C for two measurements in the
      24 hours with an interval of 6 hours at least between the two measurements.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>febrile episode</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Documented infectious episodes Collection efficiency (CD34+ cells/kilo) Mobilization days Safety</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>G-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim</condition>
  <arm_group>
    <arm_group_label>filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients mobilized with filgrastim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lenograstim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients mobilized with lenograstim</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>subcutaneous filgrastim administration</description>
    <arm_group_label>filgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenograstim</intervention_name>
    <description>subcutaneous lenograstim administration</description>
    <arm_group_label>lenograstim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 and &lt; 70 years

          2. Diagnosis of multiple myeloma

          3. ECOG &lt; 2 to be evaluated at baseline, after the induction chemotherapy

          4. Indication to the mobilization with high dose cyclophosphamide chemotherapy

          5. Normal blood counts: neutrophils &gt; 1500/μl; platelets &gt; 100.000/μl; hemoglobin &gt; 10
             g/dl.

          6. Liver and renal function: SGOT/AST, SGPT/ALT; bilirubin &lt; 1.5 times the upper limit of
             the normal ranges; creatinine &lt; 2 times the upper limit of the normal ranges.

          7. Interval from previous induction chemotherapy to high dose chemotherapy between 30 and
             60 days

          8. ECG e/o Echocardiogram within age related normal range

          9. Negative HCV and HbsAg

         10. Must be willing and able to fill in the patient's diary

         11. Written informed consent

        Exclusion Criteria:

          1. Documented and/or suspected infections

          2. Uncontrolled concurrent illness

          3. Documented cardiac dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Layton JE, Hall NE. The interaction of G-CSF with its receptor. Front Biosci. 2006 Sep 1;11:3181-9. Review.</citation>
    <PMID>16720384</PMID>
  </reference>
  <reference>
    <citation>Martin-Christin F. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs. 2001 Mar;12(3):185-91. Review.</citation>
    <PMID>11290864</PMID>
  </reference>
  <reference>
    <citation>Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). Eur J Cancer. 1994;30A Suppl 3:S7-11. Review.</citation>
    <PMID>7535073</PMID>
  </reference>
  <reference>
    <citation>Carter CR, Whitmore KM, Thorpe R. The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4.</citation>
    <PMID>14657210</PMID>
  </reference>
  <reference>
    <citation>Oh-eda M, Hasegawa M, Hattori K, Kuboniwa H, Kojima T, Orita T, Tomonou K, Yamazaki T, Ochi N. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem. 1990 Jul 15;265(20):11432-5.</citation>
    <PMID>1694845</PMID>
  </reference>
  <reference>
    <citation>Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, Linch DC. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol. 1997 Aug;98(2):474-9.</citation>
    <PMID>9266953</PMID>
  </reference>
  <reference>
    <citation>Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10(11):1235-44. Review.</citation>
    <PMID>15078138</PMID>
  </reference>
  <reference>
    <citation>Mattii L, Azzarà A, Fazzi R, Carulli G, Chimenti M, Cecconi N, Galimberti S, Petrini M. Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA. Leuk Res. 2005 Nov;29(11):1285-92.</citation>
    <PMID>15916805</PMID>
  </reference>
  <reference>
    <citation>Azzarà A, Carulli G, Rizzuti-Gullaci A, Capochiani E, Petrini M. Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis. Am J Hematol. 2001 Apr;66(4):306-7.</citation>
    <PMID>11279646</PMID>
  </reference>
  <reference>
    <citation>Ribeiro D, Veldwijk MR, Benner A, Laufs S, Wenz F, Ho AD, Fruehauf S. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion. 2007 Jun;47(6):969-80.</citation>
    <PMID>17524085</PMID>
  </reference>
  <reference>
    <citation>Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 Feb;64(2):328-40.</citation>
    <PMID>5216294</PMID>
  </reference>
  <reference>
    <citation>Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005 Jun 20;23(18):4198-214.</citation>
    <PMID>15961767</PMID>
  </reference>
  <reference>
    <citation>Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A(3):319-24.</citation>
    <PMID>7691119</PMID>
  </reference>
  <reference>
    <citation>Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003 Jan;14(1):29-35.</citation>
    <PMID>12488289</PMID>
  </reference>
  <reference>
    <citation>Höglund M, Smedmyr B, Bengtsson M, Tötterman TH, Cour-Chabernaud V, Yver A, Simonsson B. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers--a comparative study. Eur J Haematol. 1997 Sep;59(3):177-83.</citation>
    <PMID>9310126</PMID>
  </reference>
  <reference>
    <citation>de Arriba F, Lozano ML, Ortuño F, Heras I, Moraleda JM, Vicente V. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells. Br J Haematol. 1997 Feb;96(2):418-20.</citation>
    <PMID>9029036</PMID>
  </reference>
  <reference>
    <citation>Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006 Sep;134(5):517-25.</citation>
    <PMID>17018030</PMID>
  </reference>
  <reference>
    <citation>Fischer JC, Frick M, Wassmuth R, Platz A, Punzel M, Wernet P. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol. 2005 Sep;130(5):740-6.</citation>
    <PMID>16115131</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <last_update_submitted>July 2, 2009</last_update_submitted>
  <last_update_submitted_qc>July 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mario Petrini</name_title>
    <organization>University of Pisa</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

